Metabolically neutral agents such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), direct renin inhibitors, and mineralocorticoid receptor antagonists are the first-line choice of drugs for obesity-related hypertension.43 ACEs and ARBs have the added advantage of contributing to the control of obesity by improving glucose tolerance, increasing insulin levels and decreasing the levels of visceral fat﻿. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.